Found: 28
Select item for more details and to access through your institution.
Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
- Published in:
- Oncology (08909091), 2017, v. 31, n. 3, p. 159
- By:
- Publication type:
- Article
Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
- Published in:
- Oncology (08909091), 2015, v. 29, n. 11, p. 809
- By:
- Publication type:
- Article
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 8, p. 691, doi. 10.1093/oncolo/oyad178
- By:
- Publication type:
- Article
A Phase Ib Study of Single‐Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 11, p. e1604, doi. 10.1634/theoncologist.2020-0321
- By:
- Publication type:
- Article
Academic Cancer Center Phase I Program Development.
- Published in:
- Oncologist, 2017, v. 22, n. 4, p. 369, doi. 10.1634/theoncologist.2016-0409
- By:
- Publication type:
- Article
Small bowel adenocarcinoma.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 10, p. 1645, doi. 10.1002/cncr.29224
- By:
- Publication type:
- Article
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 21, p. 5403, doi. 10.1002/cncr.27526
- By:
- Publication type:
- Article
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
- Published in:
- British Journal of Cancer, 2017, v. 116, n. 8, p. 1021, doi. 10.1038/bjc.2017.40
- By:
- Publication type:
- Article
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Human pancreatic cancer-associated stellate cells remain activated after in vivo chemoradiation.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00102
- By:
- Publication type:
- Article
Human pancreatic cancer-associated stellate cells remain activated after in vivo chemoradiation.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 2, doi. 10.3389/fonc.2014.00102
- By:
- Publication type:
- Article
Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.
- Published in:
- Oncology Letters, 2016, v. 11, n. 3, p. 1645, doi. 10.3892/ol.2016.4101
- By:
- Publication type:
- Article
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 6, p. 1944, doi. 10.1002/cam4.3672
- By:
- Publication type:
- Article
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
- Published in:
- Radiation Oncology, 2013, v. 8, n. 1, p. 1, doi. 10.1186/1748-717X-8-44
- By:
- Publication type:
- Article
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Profile and potential of ixabepilone in the treatment of pancreatic cancer.
- Published in:
- Drug Design, Development & Therapy, 2014, v. 8, p. 923, doi. 10.2147/DDDT.S52964
- By:
- Publication type:
- Article
Recent Therapeutic Breakthroughs in the Treatment and Management of Pancreatic Cancer: Expert Strategies for Improved Patient Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2021, v. 24, n. 2, p. 10
- By:
- Publication type:
- Article
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.
- Published in:
- 2020
- By:
- Publication type:
- journal article
WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
- Published in:
- Scientific Reports, 2016, p. 33323, doi. 10.1038/srep33323
- By:
- Publication type:
- Article